Compare Ginkgo Bioworks Holdings Inc (DNA) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Thomson Reuters Corp — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.28 (market cap $505.73M), while Thomson Reuters Corp trades at $104.52 (market cap $45.38B). The key difference: Thomson Reuters Corp is far larger — about 89.7× Ginkgo Bioworks Holdings Inc's market cap, and Thomson Reuters Corp pays a 2.5% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | TRI | |
|---|---|---|
Market Cap | $505.73M | $45.38B |
Sector | Health | Industrials |
52-Week High | $16.14 | $178.77 |
52-Week Low | $5.48 | $76.55 |
Enterprise Value | $607.68M | $48.00B |
Dividend Yield | — | 2.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.42, down 3.01% with bearish technical signals. The company reported Q2 2026 revenue of $20M, down 48% year-over-year, while maintaining a high gross margin of 68.04% but significant net losses. Analyst sentiment is mixed with 45% buy ratings amid ongoing business model transition to autonomous laboratory systems and contract research services.
The outlook remains challenging with persistent revenue declines and negative cash flow, though recent earnings beats provide some optimism. Key risks include execution of the business pivot and path to profitability. Wall Street shows cautious optimism with majority buy ratings despite fundamental headwinds.
Thomson Reuters (TRI) trades at $102.61, down 1.68% today, with a bullish technical signal and strong fundamentals. The company reported Q2 2026 EPS of $0.99, beating estimates, and raised full-year revenue guidance. Valuation ratios include a P/E of 27.61 and a net income margin of 21.22%. Recent news highlights AI-driven growth and a joint venture with KKR.
Outlook is positive with analyst consensus favoring a Buy rating and a $102.33 price target. Key opportunities include recurring revenue growth and AI adoption, while risks involve execution of strategic initiatives and competitive pressures in the legal and tax sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
